周三，Truist Securities调整了对Incyte Corporation (NASDAQ:INCY)的立场，将该股票从买入下调至持有，同时将目标价从83美元下调至74美元。这一决定是因为这家生物制药公司即将面临其旗舰产品Jakafi的专利到期。 在最近的一份声明中，Truist Securities承认Incyte成功推出了Opzelura并努力使其管线多样化。尽管如此，该公司表示担心 ...

Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. | Incyte’s late PD-1 entrant Zynyz has chalked up a ...

Truist Securities has downgraded Incyte Corporation (NASDAQ:INCY), noting Jakafi’s (ruxolitinib) patent loss approaching in ...

Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that results from the pivotal Phase 2 AGAVE-201 trial of Niktimvo(axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients ...

生物制药公司Incyte Corporation (NASDAQ: INCY)在TD Cowen的评级中保持买入评级，目标价为80.00美元。 这一评估是在公司在欧洲肿瘤内科学会(ESMO)会议上展示更新数据之后做出的。 新数据来自其CDK2抑制剂'667的I期研究，该药物正在晚期实体瘤患者中进行测试。 更新的结果显示，随着更长的随访期和更高的剂量，'667导致的反应数量比早期结果增加。具体而言， ...

Incyte INCY announced new data from a phase I study on pipeline candidate INCB123667 in patients with advanced solid ...

Incyte Corp (INCY) stock saw a modest uptick, ending the day at $66.82 which represents a slight increase of $1.65 or 2.53% from the prior close of $65.17. The stock opened at $66.22 and touched a low ...

Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, ...

Shares of Incyte Corp. INCY slid 1.90% to $65.17 Wednesday, on what proved to be an all-around grim trading session for the ...

Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category but picked up its first approval in the rare tumour Merkel ...

Incyte (INCY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Lebovitz from ...

This was the stock's fourth consecutive day of gains.